• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Apogee Therapeutics, Inc. - Common Stock (NQ:APGE)

    65.38 -3.51 (-5.10%)
    Streaming Delayed Price Updated: 1:56 PM EST, Feb 4, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Apogee Therapeutics, Inc. - Common Stock

    < Previous 1 2 3 4 Next >
    News headline image
    The Great Rotation: Russell 2000’s Historic 15-Day Streak Marks a Seismic Shift in Market Leadership
    In a move that has rewritten the record books of Wall Street, the small-cap-heavy Russell 2000 index recently concluded a historic 15-session winning streak of daily outperformance against the S&P 500.... 
    Via MarketMinute
    Topics Artificial Intelligence ETFs Economy
    News headline image
    What Investors Should Know About a $1.5 Million Apogee Insider Sale Amid a 60% Stock Rally ↗
    This clinical-stage biotech focused on long-acting antibody therapies reported a notable insider sale amid ongoing pipeline development. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Apogee Therapeutics Chief Medical Officer Sells $817,500 Worth of Shares After Monster December Rally ↗
    This clinical-stage biotech focused on immunology therapies reported a notable insider sale amid ongoing pipeline development. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and Outlook
    From Apogee Therapeutics
    Via GlobeNewswire
    News headline image
    Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1b Trial of APG777 in Patients with Mild-to-Moderate Asthma and 2026 Anticipated Milestones on January 6, 2026
    Webcast to be held Tuesday, January 6th at 8:00 a.m. ET 
    From Apogee Therapeutics
    Via GlobeNewswire
    News headline image
    Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results
    From Apogee Therapeutics
    Via GlobeNewswire
    News headline image
    Apogee Therapeutics Announces Positive Interim Phase 1 Results from Healthy Volunteer Trial of APG333, its Novel Half-Life Extended TSLP Antibody
    From Apogee Therapeutics
    Via GlobeNewswire
    News headline image
    Apogee Therapeutics to Participate in Upcoming Conferences
    From Apogee Therapeutics
    Via GlobeNewswire
    News headline image
    Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $345 Million
    From Apogee Therapeutics
    Via GlobeNewswire
    News headline image
    Why Apogee Therapeutics Stock Triumphed on Thursday ↗
    The company aims to raise gross proceeds of roughly $300 million in a new capital-raising effort. 
    Via The Motley Fool
    Delta Air Lines, Tilray Brands, UiPath, Akero Therapeutics, Apogee Therapeutics: Stocks Making The Biggest Moves Today ↗
    Via Stocktwits
    News headline image
    Why Apogee, A Rival To Regeneron And Sanofi, Rocketed 34% And Broke Out ↗
    The small biotech company is looking to take on Regeneron and Sanofi's blockbuster, Dupixent. 
    Via Investor's Business Daily
    News headline image
    Helen of Troy, Ferrari, Apogee Therapeutics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
     
    Via Benzinga
    News headline image
    Why Richardson Electronics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket ↗
     
    Via Benzinga
    News headline image
    Apogee Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering
    From Apogee Therapeutics
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
     
    Via Benzinga
    News headline image
    What's going on in today's after hours session ↗
    Discover the top movers in Wednesday's after-hours session and stay informed about the post-market dynamics. 
    Via Chartmill
    News headline image
    Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering
    From Apogee Therapeutics
    Via GlobeNewswire
    News headline image
    Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 Congress
    From Apogee Therapeutics
    Via GlobeNewswire
    News headline image
    Apogee Therapeutics to Participate at the Stifel 2025 Virtual Immunology and Inflammation Forum
    From Apogee Therapeutics
    Via GlobeNewswire
    News headline image
    Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results
    From Apogee Therapeutics
    Via GlobeNewswire
    News headline image
    Gold Falls 1%; ProKidney Shares Spike Higher ↗
     
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Monday's Intraday Session ↗
     
    Via Benzinga
    News headline image
    Dow Dips 1%; Mustang Bio Shares Spike Higher ↗
     
    Via Benzinga
    Topics Stocks
    News headline image
    Let's uncover which stocks are experiencing notable gaps during today's session. ↗
    Today's session on Monday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session. 
    Via Chartmill
    News headline image
    Apogee Reverses Lower Despite Promise For Twice-Yearly Eczema Shot ↗
    Apogee Therapeutics shares crumbled Monday despite promising results for what could become a twice-yearly eczema shot. 
    Via Investor's Business Daily
    News headline image
    What's going on in today's pre-market session ↗
    Wondering what's happening in Monday's pre-market session? Find an overview in this article. 
    Via Chartmill
    News headline image
    Top 2 Health Care Stocks That May Plunge This Month ↗
     
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
     
    Via Benzinga
    News headline image
    Apogee Therapeutics' Eczema Drug Provides Rapid Itch Relief In Phase 2 Trial ↗
    Apogee's APG777 showed a 71% drop in eczema severity and strong itch relief in a Phase 2 trial for atopic dermatitis. Part B is ongoing. 
    Via Benzinga
    < Previous 1 2 3 4 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.